MAIA's Phase 2 Trial Shows Eight Lung Cancer Patients Surpassing Two Years Of Survival

Eight patients in MAIA Biotechnology's Phase 2 THIO-101 trial have lived beyond two years after receiving the investigational sequence Ateganosine followed by Cemiplimab, a notable early clinical durability signal. The result is promising but based on a small cohort and remains exploratory; it could support future investor interest if corroborated by larger data sets. Monitor upcoming trial enrollment, durability/safety readouts and any regulatory updates that could materially affect valuation.

Analysis

Eight patients in MAIA Biotechnology's Phase 2 THIO-101 trial have lived beyond two years after receiving the investigational sequence Ateganosine followed by Cemiplimab, a notable early clinical durability signal. The result is promising but based on a small cohort and remains exploratory; it could support future investor interest if corroborated by larger data sets. Monitor upcoming trial enrollment, durability/safety readouts and any regulatory updates that could materially affect valuation.